Home » Stocks » Amgen

Amgen Inc. (AMGN)

Stock Price: $241.47 USD -2.12 (-0.87%)
Updated Aug 5, 2020 4:00 PM EDT - Market closed
After-hours: $242.00 +0.53 (0.22%) Aug 5, 7:51 PM

Stock Price Chart

Key Info

Market Cap 141.43B
Revenue (ttm) 24.30B
Net Income (ttm) 7.30B
Shares Out 585.69M
EPS (ttm) 12.24
PE Ratio 19.73
Forward PE 16.10
Dividend $6.40
Dividend Yield 2.65%

Stock Quote

Trading Day Aug 5, 2020
Last Price $241.47
Previous Close $243.59
Change ($) -2.12
Change (%) -0.87%
Day's Open 243.91
Day's Range 240.80 - 245.41
Day's Volume 1,736,369
52-Week Range 177.05 - 264.97

More Stats

Market Cap 141.43B
Enterprise Value 164.23B
Earnings Date (est) Nov 3, 2020
Ex-Dividend Date May 15, 2020
Shares Outstanding 585.69M
Float 584.35M
EPS (basic) 12.33
EPS (diluted) 12.24
FCF / Share 17.36
Dividend $6.40
Dividend Yield 2.65%
Earnings Yield 5.07%
FCF Yield 7.22%
Payout Ratio 49.50%
Shares Short 6.03M
Short Ratio 2.03
Short % of Float 0.94%
Beta 0.95
PE Ratio 19.73
Forward PE 16.10
P/FCF Ratio 13.85
PS Ratio 5.82
PB Ratio 13.68
Revenue 24.30B
Operating Income 9.20B
Net Income 7.30B
Free Cash Flow 10.21B
Net Cash -22.80B
Net Cash / Share -38.93
Gross Margin 78.21%
Operating Margin 37.87%
Profit Margin 30.00%
FCF Margin 42.01%
ROA 9.30%
ROE 68.05%
ROIC 22.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (29)

Buy 14
Overweight 2
Hold 11
Underweight 2
Sell 0

Analyst Consensus: Overweight

Price Target

$261.21*
(8.17% upside)
Low
185
Current: $241.47
High
308
Target: 261.21
*Average 12-month price target from 24 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue23,36223,74722,84922,99121,66220,06318,67617,26515,58215,053
Revenue Growth-1.62%3.93%-0.62%6.14%7.97%7.43%8.17%10.8%3.51%-
Gross Profit19,00619,64618,78018,82917,43515,64115,33014,06612,87412,833
Operating Income9,67410,2639,9739,7948,4706,1915,8675,5774,3125,545
Net Income7,8428,3941,9797,7226,9395,1585,0814,3453,6834,627
Shares Outstanding605661731748758759753775905960
Earnings Per Share12.8812.622.6910.249.066.706.645.524.044.79
EPS Growth2.06%369.14%-73.73%13.02%35.22%0.9%20.29%36.63%-15.66%-
Dividend Per Share5.805.284.604.003.162.441.881.440.56-
Dividend Growth9.85%14.78%15%26.58%29.51%29.79%30.56%157.14%--
Operating Cash Flow9,15011,29611,17710,3549,7318,9526,2915,8825,1195,787
Capital Expenditures-618-738-664-738-320-715-673-689-567-580
Free Cash Flow8,53210,55810,5139,6169,4118,2375,6185,1934,5525,207
Cash & Equivalents8,91129,30441,67838,08531,38227,02619,40124,06120,64117,422
Total Debt29,90333,92935,34234,59631,42930,71532,12826,52921,42813,362
Net Cash / Debt-20,992-4,6256,3363,489-47.00-3,689-12,727-2,468-7874,060
Assets59,70766,41679,95477,62671,44969,00966,12554,29848,87143,486
Liabilities50,03453,91654,71347,75143,36643,23144,02935,23829,84219,542
Book Value9,67312,50025,24129,87528,08325,77822,09619,06019,02923,944
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Amgen Inc.
Country United States
Employees 23,400
CEO Robert A. Bradway

Stock Information

Ticker Symbol AMGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NASDAQ: AMGN

Description

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; QIAGEN N.V.; and Adaptive Biotechnologies. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.